Halozyme grants director RSUs and stock options
Halozyme director Dannielle Appelhans received RSU and stock option awards that vest at the 2027 annual stockholders’ meeting.
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. (HALO) reported that director Dannielle Appelhans received equity-based compensation on September 1, 2026. She was granted 1,161 Restricted Stock Units, each representing one common share, and options to purchase 1,778 shares of common stock at an exercise price of $107.72 per share. Both the RSUs and the stock options are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported for these awards.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,939 shares
Grant/Award
2 txns
Insider
Appelhans Dannielle
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock F2 | 1,778 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F1 | 1,161 | $0.00 | $0.00 |
Holdings After Transaction:
Option to Purchase Common Stock — 1,778 contracts (Direct);
Restricted Stock Units — 1,161 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
- F2. Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.
Key Figures
RSUs granted: 1,161 shares
Options granted: 1,778 shares
Option exercise price: $107.72 per share
+3 more
6 metrics
RSUs granted
1,161 shares
Restricted Stock Units granted to director Dannielle Appelhans on September 1, 2026
Options granted
1,778 shares
Stock options granted to Dannielle Appelhans on September 1, 2026
Option exercise price
$107.72 per share
Exercise price for options to purchase 1,778 Halozyme common shares
RSU post-transaction holdings
1,161 RSUs
Total RSUs directly held by Dannielle Appelhans after the transaction
Option post-transaction holdings
1,778 options
Total options directly held by Dannielle Appelhans after the grant
Option expiration date
September 1, 2036
Expiration date of the 1,778 stock options granted
Key Terms
Restricted Stock Units, stock options, director compensation program, exercise price
4 terms
Restricted Stock Units financial
"Represents restricted stock units granted under the Issuer's director compensation program."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"Represents stock options granted under the Issuer's director compensation program."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
director compensation program financial
"granted under the Issuer's director compensation program."
exercise price financial
"conversion or exercise price 107.7200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What equity awards did Halozyme (HALO) director Dannielle Appelhans receive?
Dannielle Appelhans received 1,161 Restricted Stock Units and options to purchase 1,778 shares of Halozyme common stock on September 1, 2026, as part of the company’s director compensation program.
What is the exercise price of the new Halozyme (HALO) stock options?
The newly granted Halozyme stock options to director Dannielle Appelhans have an exercise price of $107.72 per share, with options covering 1,778 shares of common stock.
When do the new Halozyme (HALO) RSUs and options for Dannielle Appelhans vest?
Both the 1,161 RSUs and the 1,778 stock options granted to director Dannielle Appelhans are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders.
Are the Halozyme (HALO) equity grants to Dannielle Appelhans part of a director compensation program?
Yes. The filing states that both the Restricted Stock Units and the stock options were granted under Halozyme’s director compensation program.
Were the Halozyme (HALO) equity awards to Dannielle Appelhans made under a Rule 10b5-1 plan?
No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with these equity grants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
